Companies · Biotechnology
SEATTLE · Biotechnology
Diligence memoA one-page analyst read on Kineta, Inc./De — recommendation, valuation, rhythm, risks.→Kineta, Inc./De looks under-valued against its niche peers and is at-risk on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Kineta, Inc./De is one of 4293 Biotechnology companies tracked from SEATTLE. By capital raised it ranks among the largest (ahead of 94% of sector peers), and in the long tail by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 60%.
Round size and date are reported; the stage label is inferred from round size (latest is Series C — a $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.
Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 94% of sector peers (real $). Modeled value above 38% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #106 of 111.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Dianthus Therapeutics, Inc. | Series C | $121.5M | $2.1B | 4.22× |
| Satellite Biosciences, Inc. | Series C | $101.5M | $1.8B | 3.63× |
| Deepcell, Inc. | Series C | $96.9M | $1.7B | 3.38× |
| Ventus Therapeutics U.S., Inc. | Series C | $186.8M | $1.6B | 3.14× |
| Morphic Holding, Inc. | Series C | $200.6M | $1.5B | 3.04× |
| Genleap Ai Inc. | Series C | $100.0M | $1.5B | 3.00× |
| Dren Bio, Inc. | Series C | $93.1M | $1.3B | 2.70× |
| Lenz Therapeutics, Inc. | Series C | $136.2M | $1.2B | 2.49× |
| eyeBrain Medical, Inc. | Series C | $126.3M | $1.2B | 2.45× |
| A2 Biotherapeutics, Inc. | Series C | $143.1M | $1.2B | 2.42× |
| Invetx, Inc. | Series C | $70.7M | $1.2B | 2.36× |
| Hexagon Bio Inc. | Series C | $148.6M | $1.2B | 2.36× |
| Kineta, Inc./De this company | Series C | $141.6M | $34.3M | 0.07× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Series C | $70.6M | 2008-08-15 | $470.8M | $2.9B | 85% |
| Series C | $5.0M | 2014-07-31 | $33.3M | $204.8M | 85% |
| Series A | $15.0M | 2014-07-31 | $68.2M | $542.3M | 85% |
| Seed | $3.0M | 2014-07-31 | $15.1M | $133.8M | 85% |
| Series C | $22.0M | 2015-09-01 | $146.7M | $901.1M | 85% |
| Series C | $33.6M | 2020-12-22 | $224.0M | $1.1B | 90% |
| Series C | $7.5M | 2022-12-16 | $50.0M | $120.4M | 90% |
| Series C | $2.9M | 2023-10-03 | $19.3M | $34.3M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Christopher Mirabelli | — | 5 other | 2014-07 |
| JEFFREY GOLDBERG | — | 5 other | 2014-07 |
| M. James Barrett | — | 5 other | 2014-07 |
| STEPHEN KNIGHT | — | 5 other | 2014-07 |
| Christopher Walsh | — | 4 other | 2014-07 |
| BERNARD DAVITIAN | — | 3 other | 2014-07 |
| Christopher K. Mirabelli | — | 3 other | 2008-08 |
| Marion R Foote | — | 3 other | 2022-12 |
| MICHAEL CASEY | — | 3 other | 2014-07 |
| Shawn Iadonato | — | 3 other | 2022-12 |
| Christopher T. Walsh | — | 2 other | 2008-08 |
| David Arkowitz | — | 2 other | 2022-12 |
| Kim C. Drapkin | — | 2 other | 2020-12 |
| LAUREN SILVERMAN | — | 2 other | 2014-07 |
| N. Anthony Coles | — | 2 other | 2020-12 |
| Patricia L. Allen | — | 2 other | 2020-12 |
| Raymond Bartoszek | — | 2 other | 2022-12 |
| RICHARD PETERS | — | 2 other | 2020-12 |
| Craig W. Philips | — | 1 other | 2022-12 |
| Jeffery W. Kelly | — | 1 other | 2008-08 |
| Kimberlee C. Drapkin | — | 1 other | 2023-10 |
| Meenu Chhabra | — | 1 other | 2014-07 |
| Raymond R. Bartoszek | — | 1 other | 2023-10 |
| Richard A. Heyman | — | 1 other | 2020-12 |
Kineta, Inc./De is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Kineta, Inc. | Biotechnology | Series B | $87.1M | $47.0M | network4 shared operators · same sector |
| Jounce Therapeutics, Inc. | Biotechnology | Series C | $91.0M | $1.3B | network2 shared operators · same sector · same stage |
| Deciphera Pharmaceuticals, LLC | Biotechnology | Series C | $142.9M | $2.1B | network1 shared operator · same sector · same stage |
| Vanqua Bio, Inc. | Biotechnology | Series C | $136.0M | $462.9M | network1 shared operator · same sector · same stage |
| Protego Biopharma | Biotechnology | Series C | $85.0M | $179.4M | network1 shared operator · same sector · same stage |
| Leap Therapeutics, Inc. | Pharmaceuticals | Series C | $105.1M | $1.1B | network2 shared operators · same stage |
| Yumanity Holdings, LLC | Other Health Care | Series C | $103.8M | $494.4M | network2 shared operators · same stage |
| Semma Therapeutics, Inc. | Biotechnology | Series D+ | $129.3M | $4.7B | network1 shared operator · same sector |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Kineta, Inc. | Biotechnology | Series B | $47.0M | 98% |
| Kineta Immuno-Oncology, LLC | Biotechnology | Pre-Seed | $13.2M | 89% |
| Kiniksa Pharmaceuticals, Ltd. | Biotechnology | Series A | $318.1M | 88% |
| KinaRX, LLC | Biotechnology | Pre-Seed | $7.2M | 86% |
| Metsera, Inc. | Biotechnology | Series D+ | $2.1B | 86% |
| Mitera Biosciences Inc. | Biotechnology | Seed | $9.4M | 84% |
| Vineti, Inc. | Biotechnology | Series C | $2.8B | 83% |
| Ekso Bionics Holdings, Inc. | Biotechnology | Series C | $113.4M | 83% |
See where Kineta, Inc./De sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Kineta, Inc./De, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.